Clinical Report: In Memoriam of Jesús Saldaña García, Emerging Leader in Preventive Cardiology
Overview
Jesús Saldaña García was a promising Spanish cardiologist specializing in preventive cardiology and cardiac imaging, whose career was tragically cut short at age 30. He made significant contributions to cardio-oncology, including validating a key risk score for anthracycline-related cardiotoxicity, and was recognized for his methodological rigor and generosity.
Background
Jesús Saldaña García graduated from the University of Málaga and trained in cardiology at Hospital Universitario La Paz after ranking 44th in Spain’s 2020 medical residency exam. His work combined clinical cardiology with advanced statistical analysis and programming, focusing on improving data quality and clinical decision-making. He was particularly interested in preventive cardiology and cardiac imaging, applying these to cardio-oncology to anticipate and prevent cardiovascular toxicity in cancer patients. His contributions included validating the HFA-ICOS risk score, a tool for assessing anthracycline-related cardiovascular toxicity.
Data Highlights
Jesús ranked 44th nationwide in Spain’s 2020 medical residency examination (MIR). He contributed to the validation of the Heart Failure Association–International Cardio-Oncology Society (HFA-ICOS) risk score for anthracycline-related cardiovascular toxicity. He served on the Statistical Editorial Board of the European Journal of Preventive Cardiology from April 2024 and was an active member of the European Society of Cardiology and the ESC Cardio-Oncology Council’s early-career community.
Key Findings
Jesús Saldaña García was a rising expert in preventive cardiology and cardiac imaging with a focus on clinical relevance and methodological rigor.
He validated the HFA-ICOS risk score, advancing cardio-oncology risk stratification for anthracycline cardiotoxicity.
He combined clinical work with strong statistical and programming skills to improve clinical databases and research quality.
He was recognized for his ability to elevate research projects and provide clear, constructive feedback as a reviewer.
Jesús served on the Statistical Editorial Board of the European Journal of Preventive Cardiology and was active in European cardiology professional communities.
His clinical approach emphasized careful judgment, scientific rigor, and compassionate patient communication.
Clinical Implications
Jesús’s work highlights the importance of integrating advanced statistical methods and imaging techniques in preventive cardiology to improve risk stratification and personalized care, especially in cardio-oncology. His validation of the HFA-ICOS risk score supports its use in clinical practice to anticipate anthracycline-related cardiotoxicity. His example underscores the value of combining clinical expertise with methodological rigor and collaborative spirit in advancing cardiovascular care.
Conclusion
Jesús Saldaña García’s promising career embodied the future of preventive cardiology through rigorous science, clinical excellence, and humanistic care. His contributions to cardio-oncology and methodological innovation leave a lasting legacy despite his untimely passing.
References
European Journal of Preventive Cardiology, 2026 -- In Memoriam: Jesús Saldaña García
